Asset LiquidityA post-IPO lock-up on the Cortigent shares would limit immediate ability to monetize that stake and could constrain near-term financing flexibility.
Capital StructureRecent capital raises increased the share count and led analysts to lower the price target, highlighting dilution risk for existing shareholders.
Funding RequirementsThe company may need additional funding to support operations beyond current resources, potentially resulting in more equity issuance or dilutive financing terms.